Mesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million
Reuters2026/08/27 00:32- Mesoblast posted FY2026 revenue of US$120.3 million, up from US$17.2 million a year earlier, on Ryoncil launch momentum.
- Net loss narrowed 44% to US$57.5 million; gross profit rose to US$103.6 million as product sales climbed to US$115.2 million.
- R&D expense increased to US$97.5 million; selling, general and administration costs rose to US$57.3 million.
- Net operating cash spend was US$43.8 million; cash and cash equivalents ended at US$103 million following a US$125 million credit-line facility.
- Management flagged Phase 3 treatment completion for rexlemestrocel-L in chronic low back pain, with top-line results expected mid-CY2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI remains above $83.50 as Iran fires missiles following US strikes
Oil jumps more than 2% after US attack on Iran's Larak island
Itochu says no decision yet on reported Dentsu Soken tender offer
After Waller's hawkish speech, the market focuses on "rate hikes", but Morgan Stanley says balance sheet reduction is more likely.
After the Jackson Hole meeting, the market's focus has shifted to interest rate hike expectations. However, Morgan Stanley economist Carpenter pointed out that Walsh's long-standing stance on reducing the $7 trillion balance sheet should not be overlooked. It is expected that the Federal Reserve may begin a balance sheet reduction of more than $1.5 trillion next year, partially replacing rate hikes.
Crypto prices
More
